Pharma study shows drop in Q2 deal activity

We haven't quite wrapped up the season of trend reports on biotech deals for the second quarter, as PricewaterhouseCoopers today has provided another mixed bag results for dealmaking in the life sciences sector. After some heavy deal flow in the first three months of 2013, the second quarter showed a 40% slide in deal volume compared with the previous one. The good news is that deal value increased 66% in the second quarter compared with the first quarter. Study (PDF)

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.